United Kingdom
www.gsk.com

Sales: $3.7 billion

Two months ago, GSK announced plans to demerge its consumer healthcare business to form Haleon, an independent company. GSK called the move the “most significant corporate change for GSK in the last 20 years, creating two new leading companies, each with clear targets for growth and the ability to positively impact the health and lives of billions of people.”

The move was expected to take place last month.

In 2021, corporate sales were flat, while consumer healthcare sales fell 4%.

According to GSK, a third of tooth sensitivity sufferers seek a long-lasting solution to address the cause of the pain, rather than just treat the symptoms. GSK’s answer? Sensodyne Repair and Protect Deep Repair, which is available in more than 25 markets. The formula provides deep and targeted repair within the dentine tubules, holes in the tissue beneath the tooth enamel that are the source of the pain, while also providing long-lasting protection from sensitivity.

Elsewhere, GSK introduced Parodontax Active Gum Repair. It is said to be clinically proven to help reverse the early signs of gum disease. GSK says a third of people globally suffer from bleeding gums, which may be a sign of gum disease.

For Q1 2022, corporate sales soared 32%. Consumer healthcare sales jumped 14%.

Consumers continue to reach for Sensodyne, which recently launched a new formula.

United Kingdom
www.gsk.com

Sales: $3.5 billion

Corporate sales: $43.7 billion

Corporate sales rose 1%, but oral care sales increased 3%. GSK executives noted that Sensodyne Sensitivity and Gum is now available in more than 50 markets. What’s more, Sensodyne is the No. 1 dentist-recommended toothpaste, according to GSK. In fact, the company calls itself the leading “therapeutic oral health” company in the world.

For the first quarter of 2021, corporate sales fell 18% and consumer healthcare sales fell 19%. But the company noted that it remains on track to create a new consumer healthcare company in 2022. A year from now, the new GSK will be “a leading biopharma company with R&D focused on science of the immune system, genetics and advanced technologies.” At the same time, the as-yet-unnamed consumer healthcare company will house “category leading brands based on deep human understanding and trusted science.”

United Kingdom
www.gsk.com
Sales: $3.3 billion

Note: $3.3 billion for oral care products. Corporate sales: $43.1 billion

GlaxoSmithKline is on the front line in the fight against COVID-19, but the company also has a thriving oral care business. Last year, oral care sales rose 7%. Sensodyne posted double-digit, broad-based growth, with strong performance in the US and India benefitting from new product launches. Gum health also posted double-digit gains, while denture care grew mid-single digits.

Last year, GSK finalized a deal with Pfizer to combine their two consumer healthcare businesses into a joint venture. As previously announced, GSK intends to demerge the JV from the company within three years and to list the GSK Consumer Healthcare business on the UK equity market.

“The completion of the joint venture with Pfizer marks the beginning of the next phase of our transformation of GSK,” said Emma Walmsley, chief executive officer, GSK and chair of the joint venture. “This is an important moment for the group, laying the foundation for two great companies, one in pharmaceuticals and vaccines and one in consumer health.”

For the first quarter, corporate sales surged 19% and consumer healthcare sales jumped 46%—due primarily to the inclusion of the Pfizer consumer healthcare portfolio. Oral care sales rose 11% in the quarter, helped by gains from Sensodyne, and gum and denture care.

United Kingdom
www.gsk.com

Sales: $3.3 billion for oral care products. Corporate Sales: $38.7 billion.

Corporate sales grew 2% in 2018, driven by new pharmaceutical products. Oral health sales grew 1% to $3.3 billion, as increased competitive pressures in Europe were offset by double digit growth from Sensodyne in a number of international markets, including India and Turkey, and strong single-digit relief in the US driven by Sensodyne Rapid Relief. The company’s premium gum health brand Parodontax/Corsodyl became the world’s fastest growing global toothpaste, outperforming the market four-fold, driven by continued momentum in the US since its launch in 2017, and a strategic brand repositioning across 40 countries.

CEO Emma Walmsley, who stepped into the role in 2017, has been shaking things up at the three-century old global drug company. During 2018, GSK made progress against its performance priority to deliver sales growth, operating margin improvements and attractive returns, by buying Novartis out of its consumer healthcare joint venture for $13 billion in June. This gave GSK full control of products including Sensodyne toothpaste, Panadol headache tablets, muscle gel Voltaren and Nicotinell patches.

In December, the company announced the sale of Horlicks and other consumer nutrition brands to Unilever. As part of this transaction, GSK announced that it would merge its 72.5% stake in GlaxoSmithKline Consumer Healthcare Limited in India with Hindustan Unilever Limited. The proposed merger includes a distribution arrangement, which will allow Hindustan Unilever Limited to leverage its scale and strong reach to sell and distribute GSK’s OTC and oral health brands in India. The transaction is expected to close by the end of 2019.

At the end of 2018, GSK reached an agreement with Pfizer to combine its consumer healthcare businesses to create a new world-leading joint venture with combined sales of approximately $12.7 billion. This brings together two highly complementary portfolios of trusted consumer healthcare brands, including GSK’s Sensodyne, Voltaren and Panadol and Pfizer’s, Advil, Centrum and Caltrate. The new consumer health giant will have a market share of 7.3%, which is well ahead of its nearest rivals, Johnson & Johnson, Bayer and Sanofi. Together, these moves give GSK the confidence to improve its margin target to mid-to-high-20s by 2022, assuming the close of the transaction with Pfizer.

For the first quarter of 2019, consumer healthcare sales declined 1%, reflecting growth in wellness, oral health and nutrition, offset by a decline in skin health, the divestments of some smaller brands including Horlicks and MaxiNutrition in the UK and the impact of the implementation of the Goods & Services Tax in India.

In June, GSK formed a partnership with the University of California in which the company will provide up to $67 million over five years to fund research using the gene-editing tool CRISPR to develop new medicines. The partnership will create a new lab, called the Laboratory for Genomics Research, near UCSF’s Mission Bay campus in San Francisco, and jobs for 24 university employees and up to 14 GSK employees.

United Kingdom
www.gsk.com

Sales: $3.1 billion oral care products. Corporate sales: $37.3 billion.

Corporate sales rose 8%. Oral health sales grew 11%, as Sensodyne posted a 12% increase in sales, with strong delivery in all regions following the roll out of next generation Sensodyne Rapid Relief and the launch of Pronamel Strong & Bright. Sales of Parodontax continued to grow strongly, reflecting double-digit performances in Europe and international markets, driven by a brand reset and increases in dentist recommendations, as well as the US launch in the first quarter. Denture care grew in mid-single digits with double-digit growth in emerging markets partly offset by slower consumption growth in the US and Germany.

For the first quarter of 2018, corporate sales fell 2% and consumer healthcare sales dipped 3%. Still, GSK noted that oral care sales had a good three-month performance, adding 2% on the strength of Sensodyne sales. Furthermore, sales of denture care and Paradontax grew in double-digits, thanks to increased dentist recommendations and the role out of Polident Max Seal and Paradontax Complete Protection.

United Kingdom
www.gsk.com

Sales: $2.4 billion

GlaxoSmithKline is the No. 3 player in the global oral care segment. Last year, Sensodyne became the company’s first £1 billion consumer health care brand, which makes it the third-largest product by sales in the GSK portfolio.

For Q1 2017, sales rose in every segment, although consumer healthcare sales rose just 2%. However, oral care sales rose 7% to $715 million in the period. Sensodyne drove sales higher, as did Parodontax, reflecting gains in Europe and International markets, as well as the brand’s US launch. The newest toothpaste in the Sensodyne lineup is Deep Clean, which is said to work inside the tooth to help calm the nerves for 24 hours, while providing all of the benefits of regular toothpaste.

On April 1, Emma Walmsley became CEO at GSK, succeeding Andrew Witty who retired. Walmsley had been president of the consumer healthcare division. She joined GSK in 2010 from L’Oréal, where she held a variety of marketing and management roles in the UK, Europe and US.

GSK may be leading the way in oral care research, but the company is always looking for outside help. At innovation.gsk.com, potential partners can view a list of current oral care needs, which include plaque-reducing or plaque-inhibiting solutions, gum health and enamel health.

United Kingdom
www.gsk.com
Sales: $2.8 billion

Corporate sales rose 1% last year. GlaxoSmithKline is best known for its pharmaceutical business, but the company maintains it is the No. 3 player in the global oral care market (behind Colgate and P&G). Last year, Sensodyne led the way, with double-digit sales gains. Now, the toothpaste is closing in on annual sales of £1 billion. In fact, thanks to the successful launch of Sensodyne Complete, the brand is the leading toothpaste in Japan.

Earlier this year, GSK earned a patent for a formula designed to protect teeth against dental erosion and/or toothwear. It is comprised of applying to teeth an oral care composition comprising sodium fluoride, potassium nitrate, and a triple polymer system consisting of xanthan gum, carboxymethylcellulose and copovidone.

In Q1 2016, consumer health care sales rose 26% to more than  £1.7 billion due primarily to favorable exchange rates. Oral care sales played a role in the increase, but GSK noted that Aquafresh sales declined due to competitive pressure. That decline was more than offset by gains made by Sensodyne, gum health and denture products.

United Kingdom
www.gsk.com
Sales: $2.8 billion

A nearly $3 billion toothpaste business is nothing to frown at—unless it’s part of an overall pharma business that’s involved in a $16 billion deal with a competitor that promises to reshape its vaccine business. That’s been the case at GSK, which completed a three-part transaction with Novartis earlier this year involving, vaccines, oncology and a consumer healthcare JV.
Despite that sizeable distraction, GSK’s oral care sales rose 4% last year, a bright spot for a pharmaceutical company that reported a 3% decline in corporate sales. Consumer demand for specialty formulas provided a lift, as sales of Sensodyne for sensitivity and acid erosion, as well as gum health, each rose 11%. Growth was reported in emerging and well-established markets, with notable successes in China and North America, according to GSK.

The oral care business got off to a fast start in 2015, as first quarter sales rose on the strength of the Sensodyne Repair & Protect launch.

United Kingdom
www.gsk.com
Sales: $3.0 billion

GSK’s story in 2013 is nearly identical to what it reported in 2012. Oral care sale rose 6% last year driven by strong consumer demand for Sensodyne toothpaste for Sensitivity and Acid Erosion, which was up 15%, and sales of denture care brands, which increased 9%. However, sales of Aquafresh fell 12%.

Back in 2012, oral care sales were up 5%, driven by a double-digit gain for Sensodyne Sensitivity and Acid Erosion. Aquafresh sales fell back in 2012, too. But the drop was a more modest 2%.

For the first quarter of 2014, oral care sales increased 5% to $756 million. Sales of Sensodyne increased 13% and denture care sales rose 5% to more than offset a 14% decline in sales of Aquafresh, which the company blamed on now-resolved supply issues.

United Kingdom
www.gsk.com

Sales: $2.9 billion

With oral care sales of nearly $3 billion, GlaxoSmithKline is a major player in the global personal care market—even if toothpaste and related products account for just a fraction of the pharmaceutical giant’s corporate sales of $42.6 billion.

Oral care sales rose 5% last year, driven by sales of Sensodyne Sensitivity & Acid Erosion, which posted a 15% increase in sales. GSK said that strong results from denture care products also helped to offset a 2% decline in Aquafresh sales.

GSK says its new Sensodyne Repair Sensitive Teeth’s active ingredient, stannous fluoride, forms a repairing layer over sensitive teeth when used twice a day.

For the first quarter of 2013, oral care sales were $749 million, an increase of less than 2%.

United Kingdom
www.gsk.com

Sales: $2.7 billion

GSK is one of the world’s leading pharmaceutical companies with corporate sales of nearly $44 billion last year.

Oral care product sales rose 8% last year, due in large part to the success of the Sensodyne brand, which grew 16%, driven by the launch of Sensodyne Repair & Protect, and the brand’s ongoing roll-out in emerging markets. Denture care sales were up, thanks to double-digit gains in emerging markets, as well as growth in Japan and the US, according to the firm.

In October, 2011, Emma Walmsley was named president, consumer healthcare worldwide. She had been president of consumer health care, Europe. Walmsley joined GSK from L’Oréal where she worked for 17 years, holding a variety of marketing and general management roles in Paris, London and New York.

To keep growing in 2012, GlaxoSmithKline has refocused its consumer healthcare portfolio into four, large, high-value categories: wellness, oral health, nutrition and skin health. The company’s goal is to become the world’s most successful fast-moving consumer healthcare company, driven by science and values.

To help get there, in January, GSK sold several non-core brands to Prestige Brands Holdings for about $680 million. The brands, including BC, Goody’s, Beano, Ecotrin, FiberChoice and Tagamet, had sales of approximately $200 million in 2011.

For the first quarter of 2012, consumer health care sales rose 1%, driven by an 11% gain in oral care sales, which reached $739 million. The company noted that Sensodyne registered its 12th consecutive quarter of double-digit growth.

United Kingdom

www.gsk.com

Sales: $2.4 billion

GlaxoSmithKline is overwhelmingly a pharmaceutical company. In fact, it only makes The International Top 30 list based on its oral care business, but then, GSK sells some of the world’s best-known toothpaste brands. Last year, oral care sales rose 6%, led by a strong performance by Sensodyne, a 50-year-old brand. The company proudly notes that Sensodyne has been the world’s fastest growing toothpaste brand for the past five years. Following a 2010 launch in India, Sensodyne is now available in 124 countries. Biotene, the dry mouth treatment that GSK bought in 2008, performed well too. On the downside, sales of Aquafresh declined slightly last year.

For the first quarter of 2011, oral care sales jumped 12%, led by Sensodyne, which benefitted from the launch of Sensodyne Rapid Relief, which began in 2010, as well as the launch of Sensodyne Repair and Protect that began in the first quarter of this year.

In the US, Sensodyne, Poligrip and Biotene all posted good gains, which helped offset lower sales of Aquafresh.

United Kingdom
www.gsk.com
Sales: $2.7 billion

Sales of oral healthcare products rose 7% to more than $2.3 billion. Sensodyne performed strongly with sales up 13% to $715 million. Denture care sales grew 8% to $526 million. Sales of Aquafresh declined 1%, as a reduction in the U.S. “white trays” market offset growth of 5% in the U.S. The Aquafresh toothpaste brand was helped by the launch of the new iso-active product.

The iso-active foaming gel within its Aquafresh and Sensodyne families is packaged in bag-in-valve canisters and the gel-to-foam action is a result of the inclusion of isopentane, which responds to increases in temperature, such as in the user’s mouth once she starts brushing. The foaming action disperses active ingredients quickly to penetrate hard-to-reach areas of the mouth—a critical component to improving overall oral health, according to GSK. Available in five different varieties, the Iso-active technology has been available in Europe since 2007 and debuted in the U.S. last summer.

For the first quarter of 2010, corporate sales rose 13% to $11.5 billion. Oral care sales rose 5% to $594 million. Sales of Sensodyne surged 21% to $207 million, offsetting a 29% decline in Poligrip sales following the company’s decision in February to end production of the zinc-containing product and to move to zinc-free alternatives, which reached markets in May. The move came after several lawsuits regarding the use of zinc in denture cream. Zinc was added to the formulas in the 1990s to boost holding power, but zinc can trigger muscle weakness and poor balance in large doses, according to lawsuits. According to experts, zinc causes the body to leach copper, which is needed for proper muscle and nerve function.

Little more than a year ago, GSK completed its acquisition of Stiefel Laboratories, Inc., billed as the world’s largest independent dermatology company for $2.9 billion. GSK also assumed $400 million of net debt.

In announcing the deal, Andrew Witty, chief executive officer of GSK, said, “As part of our strategy to grow and diversify GSK’s business, we are continuing to make new investments through targeted acquisitions. This transaction will create a new world-leading, specialist dermatology business and re-energise our existing dermatology products. The addition of Stiefel’s broad portfolio will provide immediate new revenue flows to GSK with significant opportunities to enhance growth through leveraging our existing global commercial infrastructure and manufacturing capability. We look forward to working with Stiefel to develop this exciting opportunity.”

The new business will have a broad portfolio of dermatology products including Stiefel brands Duac for acne, Olux E for dermatitis and Soriatane for the treatment of severe psoriasis.Stiefel also sells the Revaléskin skin care brand, which is sold through aesthetic physicians.

Sales of Stiefel’s products for the calendar year ended 2008 were approximately $900 million, with prescription dermatology products accounting for approximately $550 million.

United Kingdom
www.gsk.com
Sales: $2.2 billion

With corporate revenues of $45.2 billion, sales of GlaxoSmithKline’s oral healthcare products rose 6% to $2.2 billion. There were strong performances from Sensodyne (up 12% to $673 million) and Aquafresh (up 3% to $838 million). According to GSK, Sensodyne’s growth represented 35% of world toothpaste growth in 2008 in markets where the company competes.

Via its acquisition of Stiefel, the new Impruv skin care line is part of GSK’s personal care stable.

In October, GSK expanded its oral care business by acquiring leading dry mouth treatment brand Biotene from Laclede in a $170 million deal. The range, which includes mouthwash, toothpaste, gel, spray and gum formulations, recorded sales of $50 million in 2007, up 17% over 2006. And, there appears to be room for further growth. Globally, dry mouth—known as xerostomia—is as prevalent as dental sensitivity, affecting approximately 20% of the adult population.

“The acquisition of Biotene extends our portfolio in therapeutic oral healthcare to include a proven treatment for dry mouth,” John Clarke, president, GSK Consumer Healthcare, said when the deal was announced. “This opportunity leverages our global capability with dental and medical professionals and is a further step towards our goal in GSK of building and growing a diversified healthcare business.”

Oral care may be GSK’s main focus in personal care, however the pharma giant expanded its dermatological and skin care expertise this year by acquiring Stiefel, one of the world’s largest independent dermatology companies. While Stiefel’s business is centered on prescription treatments for acne and other conditions, it offers non-doctor dispensed brands too, such as Impruv, a new line of dry skin products launched in March. Stiefel also touts Revaléskin skin care products, which are available through aesthetic physicians.

United Kingdom
www.gsk.com
Sales: $2.1 billion

Sales:

$2.1 billion for oral care. Corporate sales: $45.4 billion.

GSK’s oral care sales rose 8% to nearly $2.1 billion. Sales of Aquafresh rose 12%, spurred by the success of new Aquafresh White Trays. Sensodyne’s sales jumped 16%, driven by Senosdyne ProNamel.

GSK is touting Aquafresh iso-active foaming gel, a new foaming gel proven to remove significantly more anaerobic bacteria and volatile sulphur compound (VSC)-producing organisms than ordinary toothpaste. According to the company, the gel-to-foam action generates twice the volume of ordinary toothpaste, spreads ingredients and penetrates hard-to-reach places to help remove debris and bacteria and fight odor.

GSK is squarely committed to promoting oral care health from both a professional and consumer standpoint. Along those lines, in November GSK inaugurated the Aquafresh Science Academy in Weybridge, UK. Supported by a global website, GSK aims to provide a valuable information resource for dental professionals across the world. More recently, GSK unveiled a $7 million campaign in the UK featuring its five main oral care brands—Aquafresh, Corsodyl, Macleans, Poligrip and Sensodyne. The campaign’s website, www.loveyourmouth.co.uk, features a “mouth match” test that helps consumers find products that will deliver the oral health benefits they need.